StockWatch
·
UJJIVAN SMALL FINANCE BANK · Q2 FY27 · THE VERDICT

The PAT Surge That Signals Deceleration Ahead

Net profit surged 199.9% YoY to ₹365 Cr on exceptional cost leverage, yet management guided for 12–14% loan growth in H2—a sharp pivot from 32.1% H1. The market is pricing this slowdown, but insurance income cliff and rate headwind risks remain underpriced.

Q2 FY27 resultsUJJIVANSFBUjjivan Small Finance Bank Ltd22 Oct 2026 · 6 min read
Reported PAT

₹365 Cr

+199.9% YoY | NII +35% YoY

H1 Loan Growth

32.1%

Beat 25% FY guidance; H2 guidance 12–14%

NIM

8.45%

FY target 8.35% | 10 bps rate drag

Deposits

₹50,643 Cr

+29.2% YoY; CASA +2% moderation

The real story: What Q2 delivered vs. what's ahead

Ujjivan's Q2 is a quarter of two halves. The headline profit growth of 199.9% YoY is real and driven by organic momentum: loan book up 32.1% H1 YoY, deposits crossed the ₹50,000 Cr milestone, and net interest income surged 35%. Cost discipline was tight — operating expenses grew just 6% quarter-on-quarter despite 104 branch additions and 1,335 new hires — delivering operating margin of 27.6%. But peel back the guidance, and management is waving a yellow flag. H2 loan growth guidance of 12–14% is a 58% deceleration from H1's 32.1%, signaling that the company is deliberately calibrating deployment in the face of macro headwinds. That recalibration, coupled with three new pressure points—rate pass-through eating 10 bps of NIM, insurance income facing regulatory uncertainty worth ₹90+ Cr annualized, and CASA moderation in a rising-rate environment—paints a very different picture from the profit headline.

Management's claims vs. what holds up

Key call claims and how they score against the numbers

Strong loan growth anchored on well-rounded credit expansion.

Gross loan book ₹45,699 Cr, +32.1% YoY H1; housing +38.1%, micro-mortgages +85.7%, gold +209.8% YoY. Loan-to-deposits ratio manageable.

Supported

NII rising 35% YoY supports interest income growth run rate.

NII ₹1,244 Cr, +35% YoY confirmed. But PAT growth 199.9% YoY — far outpacing NII, showing cost leverage.

Supported

Asset quality remained steady; Bucket X collection efficiency 99.7%.

Bucket X collection 99.7%, PAR in decimal points only. MFI slippages 1.85% H1 annualized. Micro-mortgages (30 months old) expected to peak ~2.5% PAR, just below 3%.

Supported

NIM 8.35% FY despite 10 bps rate headwind; mix shift and deposit repricing to offset.

Q2 NIM 8.45%; FY guidance 8.35% (10 bps lower). Mix to secured is helping, but deposit cost rising — CASA moderation visible. Tail risk if rates move faster.

Supported, but pressured

Insurance income at risk from IRDAI consultation; contingency plans explored.

IRDAI draft paper released; final guideline Oct 25. Insurance income ~₹90 Cr annualized (50% of misc income). Mgmt cannot quantify downside until Oct 25.

Partial — uncertainty not resolved

What changed on this call

  • Opex/ATA guidance improved from 6.4% to 6.2% FY27

  • H2 loan growth recalibrated to 12–14% (vs 32.1% H1)

  • NIM guidance adjusted downward to 8.35% (from prior 8.45% trend)

  • Insurance income now uncertain pending IRDAI Oct 25 guideline

  • CRAR boosted by 33 bps to 20.69% via ₹409 Cr capital raise

  • Secured portfolio targeting 56% by year-end (currently 52.1%)

How the street is reading it

The stock is trading at ₹61.99, down 16.16% from its all-time high of ₹73.94. It sits below its 20-day moving average (₹64.08) and 50-day average (₹66.25), though holding above the 200-day (₹61.06). RSI at 43.4 signals neutral momentum, and volume is trending higher—a sign that the deceleration signal is being digested. The market's 16% drawdown from ATH reflects a repricing of growth expectations, but it may not yet fully account for the H2 slowdown coupled with insurance income cliff risk. FII ownership has trimmed 42 basis points to 16.81% in Q1 FY27, while DII has added 232 bps to 33.45%—domestic institutions are staying, but foreign flows are cautious. This divergence suggests the market is in two minds: domestic buying on the structural story (secured shift, non-micro banking growth, 20%+ CRAR), but foreign investors waiting for clarity on rate trajectory and near-term growth.

Bull-bear ledger

The two-sided case
  • Exceptional Q2 profit growth (199.9% YoY) on cost leverage

  • Loan growth H1 beat 25% FY target at 32.1%; full-year tracking to meet or beat

  • Deposit momentum strong: crossed ₹50,000 Cr, CASA at 26%

  • Secured asset shift (52% today → 56% target) de-risks the portfolio and supports ROA

  • Capital raise ₹409 Cr closed; CRAR healthy at 20.69%

  • H2 guidance 12–14% signals 58% deceleration from H1 32.1%

  • NIM compression 10 bps FY despite rate pass-through hedges; further tightening risk

  • Insurance income ₹90+ Cr annualized at cliff risk pending IRDAI Oct 25 guideline

  • CASA moderation visible; deposit cost inflation outpacing repricing strategies

  • Drought macro risk in Karnataka/Maharashtra; collections 99.7% but contingent on rains

Risks, ranked by how much they should concern a holder

Critical risks that could derail the story

IRDAI insurance commission regulation (guideline due Oct 25)

High

Insurance income ~₹90 Cr annualized is ~50% of misc income. Mgmt expects 'material cliff' if final guidelines change commission structure. No contingency quantified yet.

Repo rate pass-through faster than hedged; NIM compression beyond 8.35%

High

Repo +25 bps already assumes 10 bps NIM drag. Further tightening, continued deposit cost inflation, and yield compression in secured assets could compress margins beyond guidance.

CASA moderation and deposit cost inflation outpacing repricing

Medium

CASA at 26%, target 30%, but cost of funds rising despite DA repricing strategy. If deposit churn accelerates, funding costs could exceed 6.9% baseline and compress profitability.

Drought in Karnataka/Maharashtra sustained; PAR spike in agri portfolio

Medium

Agri exposure in Karnataka 20–25% of ₹2,400 Cr portfolio. Collection efficiency 99.7% today, but prolonged drought could slow agri customer cash flows and spike PAR.

MD transition uncertainty (search ongoing, 3–4 months to completion)

Low

Sanjeev Nautiyal retired early (health); NRC search underway (Sep–Dec completion). Interim leadership stable, but strategic clarity deferred. Succession credibility important for growth.

The debate: Can Ujjivan sustain growth amid headwinds?

What to watch next

Concrete catalysts and milestones for resolution
  • 1 · IRDAI insurance commission final guideline (due Oct 25)

    This is the near-term binary. If the regulator cuts commission structure materially, non-interest income faces a cliff. Mgmt will adjust branch/TPP strategy post-guideline. This will be the largest driver of H2 profit trajectory.

  • 2 · H2 loan growth actuals (track Q3 & Q4 disbursements)

    Can Ujjivan deliver the guided 12–14% H2 growth despite rate headwinds and CASA moderation? This resolves whether the 32.1% H1 was a sprint or a sustainable pace. Full-year loan growth tracking to meet or beat the 25% target is the credibility test.

  • 3 · NIM trajectory in a rising-rate environment (Q3 onwards)

    Q2 NIM 8.45%, FY target 8.35%. If repo rate hikes continue or deposit costs accelerate beyond repricing, NIM could compress below 8.35%. Monitor deposit-repricing actions (DA rollout) and CASA stabilization in Q3.

  • 4 · MD successor appointment (expected by ~Dec 2026)

    NRC search underway; 3–4 month timeline. Successor clarity will be a credibility event. Any extended vacancy or external hire friction could weigh on sentiment.

  • 5 · Secured portfolio milestone (56% target by FY-end)

    On track as of Q2 (52.1%). Achieving 56% by Mar-27 validates the strategic pivot and supports ROA improvement narrative. This is an execution test, not a binary.

The number to track from here

Q2 delivered ₹365 Cr net profit, but that headline masks the real earnings power of the bank. Strip out the cost leverage from NII growth (35% YoY) and hold opex flat, and the organic PAT run-rate is more like ₹245–260 Cr—a 20% growth story, not 200%. That's a good quarter, not exceptional. H2 loan growth guidance of 12–14% will naturally dampen NII growth, and if the insurance income cliff materializes post-Oct 25, H2 bottom-line could flatten or decline quarter-on-quarter. Track H2 organic PAT (adjusted for any one-time insurance income hit) — that's where the true earnings trajectory reveals itself. If H2 delivers ₹280+ Cr PAT organically despite rate/CASA headwinds, the bull case holds. If it lands below ₹250 Cr, the deceleration is real and valuation likely re-rates downward.

Ujjivan Small Finance Bank's Q2 is a bifurcated story: exceptional profit growth headline masking emerging margin and growth headwinds. The company has executed well on its structural strategy—secured asset shift, non-micro banking expansion, deposit momentum, capital raise—but it is also signaling caution via H2 growth guidance that's 58% lower than H1. Combined with regulatory uncertainty on insurance income and rate pass-through drag on margins, this is not a story to chase at all-time highs. It is, however, a story worth holding for the long-term structural case, provided near-term catalysts (IRDAI outcome, H2 growth delivery, NIM stability) confirm management's ability to navigate the headwinds. The market's 16% drawdown from ATH offers a reasonable entry, but the next 90 days are binary on execution. Hold pending clarity.

Informational and educational content only. Not investment advice.